GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gossamer Bio Inc (NAS:GOSS) » Definitions » Cash Flow from Investing

Gossamer Bio (Gossamer Bio) Cash Flow from Investing : $-58.02 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Gossamer Bio Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Gossamer Bio spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $86.13 Mil on purchasing investments. It gained $147.80 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Gossamer Bio gained $61.67 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Gossamer Bio Cash Flow from Investing Historical Data

The historical data trend for Gossamer Bio's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gossamer Bio Cash Flow from Investing Chart

Gossamer Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial -147.14 215.34 -117.43 -1.04 -110.97

Gossamer Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.72 12.94 -118.26 -14.37 61.67

Gossamer Bio Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Gossamer Bio's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Gossamer Bio's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-58.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gossamer Bio  (NAS:GOSS) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Gossamer Bio's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Gossamer Bio spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Gossamer Bio's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Gossamer Bio gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Gossamer Bio's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Gossamer Bio spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Gossamer Bio's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Gossamer Bio gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Gossamer Bio's purchase of investment for the three months ended in Mar. 2024 was $-86.13 Mil. It means Gossamer Bio spent {stock_data.stock.currency_symbol}}86.13 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Gossamer Bio's sale of investment for the three months ended in Mar. 2024 was $147.80 Mil. It means Gossamer Bio gained $147.80 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Gossamer Bio's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means Gossamer Bio paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Gossamer Bio's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means Gossamer Bio paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Gossamer Bio's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means Gossamer Bio paid $0.00 Mil for other investing activities.


Gossamer Bio Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Gossamer Bio's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Gossamer Bio (Gossamer Bio) Business Description

Traded in Other Exchanges
Address
3013 Science Park Road, Suite 200, San Diego, CA, USA, 92121
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Executives
Sandra Milligan director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Bryan Giraudo officer: Chief Financial Officer 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
Richard Aranda officer: Chief Medical Officer 3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Faheem Hasnain director, officer: Executive Chairman 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Waage Christian officer: EVP & General Counsel RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Caryn Peterson officer: EVP, Regulatory Affairs 3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Laura Carter officer: Chief Scientific Officer 3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Luisa Salter-cid officer: Chief Scientific Officer C/O GOSSAMER BIO, INC., 3013 SCIENCE PARK ROAD, SUITE 200, SAN DIEGO CA 92121
Jakob Dupont officer: Chief Medical Officer C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Sheila Gujrathi director, officer: President & CEO 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Omega Fund V Gp, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V Gp Manager, Ltd. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Otello Stampacchia director, 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Russell J. Cox director C/O JAZZ PHARMACEUTICALS, PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2